Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Aurinia Pharmaceuticals Inc. (AUPH) Insider Trading Activity
Healthcare • Biotechnology • 300 employees
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Total Value
$17,654,232.42
Total Shares
3,445,079
Average Trade Value
$490,395.35
Most Active Insider
Tang Kevin
Total Activity: $23,535,126
Largest Single Transaction
$4,545,000
by Tang Kevin on Dec 9, 2024
30-Day Activity
7 Transactions
Volume: 410,339 shares
Value: $3,278,728
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
| Mar 4, 2025 | 148,038 | $1,184,304 | 9,429,500 (+1.6%) | Purchase | ||
| Mar 4, 2025 | 500,000 | $3,960,000 | 9,929,500 (+5.0%) | Purchase | ||
|
Chief Executive Officer
Director, Officer
|
Mar 4, 2025 | 164,947 | $1,306,380 | 1,788,945 (-9.2%) | Sale | |
|
Chief Financial Officer
Officer
|
Mar 4, 2025 | 56,154 | $444,740 | 577,361 (-9.7%) | Sale | |
|
Evp, General Counsel
Officer
|
Mar 4, 2025 | 57,607 | $456,247 | 509,276 (-11.3%) | Sale | |
|
Chief Operating Officer
Officer
|
Mar 4, 2025 | 58,991 | $467,209 | 680,465 (-8.7%) | Sale | |
| Mar 4, 2025 | 100,000 | $809,000 | 10,029,500 (+1.0%) | Purchase | ||
|
Chief Medical Officer
Officer
|
Mar 3, 2025 | 12,239 | $97,912 | 161,789 (-7.6%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Mar 3, 2025 | 333,705 | $0 | 2,149,485 (+15.5%) | Grant | |
| Mar 3, 2025 | 351,962 | $2,822,735 | 9,281,462 (+3.8%) | Purchase | ||
| Mar 3, 2025 | 100,720 | $802,738 | 8,929,500 (+1.1%) | Purchase | ||
|
Chief Operating Officer
Officer
|
Mar 3, 2025 | 135,567 | $0 | 805,358 (+16.8%) | Grant | |
|
Chief Operating Officer
Officer
|
Mar 3, 2025 | 65,902 | $527,216 | 739,456 (-8.9%) | Sale | |
|
Evp, General Counsel
Officer
|
Mar 3, 2025 | 102,406 | $0 | 631,755 (+16.2%) | Grant | |
|
Evp, General Counsel
Officer
|
Mar 3, 2025 | 64,872 | $518,976 | 566,883 (-11.4%) | Sale | |
|
Chief Financial Officer
Officer
|
Mar 3, 2025 | 61,859 | $494,872 | 633,515 (-9.8%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Mar 3, 2025 | 195,593 | $1,564,744 | 1,953,892 (-10.0%) | Sale | |
|
Chief Financial Officer
Officer
|
Mar 3, 2025 | 114,711 | $0 | 695,374 (+16.5%) | Grant | |
|
Chief Financial Officer
Officer
|
Feb 28, 2025 | 81,457 | $0 | 580,663 (+14.0%) | Grant | |
|
Evp, General Counsel
Officer
|
Feb 28, 2025 | 84,106 | $0 | 529,349 (+15.9%) | Grant | |
|
Chief Operating Officer
Officer
|
Feb 28, 2025 | 82,781 | $0 | 669,791 (+12.4%) | Grant | |
|
Chief Executive Officer
Director, Officer
|
Feb 28, 2025 | 290,728 | $0 | 1,815,780 (+16.0%) | Grant | |
|
Chief Medical Officer
Officer
|
Feb 28, 2025 | 62,583 | $10,000 | 174,028 (+36.0%) | Grant | |
| Feb 28, 2025 | 399,280 | $3,134,348 | 8,828,780 (+4.5%) | Purchase | ||
| Dec 9, 2024 | 500,000 | $4,545,000 | 8,429,500 (+5.9%) | Purchase | ||
| Dec 6, 2024 | 400,000 | $3,604,000 | 7,929,500 (+5.0%) | Purchase | ||
| Dec 5, 2024 | 300,000 | $2,673,000 | 7,529,500 (+4.0%) | Purchase | ||
|
Director
|
Nov 21, 2024 | 12,135 | $10,000 | 25,491 (+47.6%) | Grant | |
|
Director
|
Nov 21, 2024 | 12,135 | $10,000 | 56,499 (+21.5%) | Grant | |
|
Director
|
Nov 21, 2024 | 20,631 | $10,000 | 20,631 (+100.0%) | Grant | |
|
Director
|
Nov 21, 2024 | 12,135 | $10,000 | 24,807 (+48.9%) | Grant | |
|
Director
|
Nov 21, 2024 | 12,135 | $10,000 | 25,053 (+48.4%) | Grant | |
|
Director
|
Nov 11, 2024 | 5,241 | $44,182 | 12,672 (-41.4%) | Sale | |
|
Director
|
Nov 11, 2024 | 4,557 | $38,416 | 13,356 (-34.1%) | Sale | |
|
Director
|
Nov 8, 2024 | 17,913 | $10,000 | 17,913 (+100.0%) | Exercise/Conversion | |
|
Director
|
Nov 8, 2024 | 17,913 | $10,000 | 17,913 (+100.0%) | Exercise/Conversion |